| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Mineralys Therapeutics, Inc. (MLYS) has 8 insiders with recent SEC Form 4 filings, including 1 buy and 30 sells. MLYS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 7.90M | $233.48M | - | |
| Dir | 5.46M | $161.19M | - | |
| CEO | 689.3K | $20.36M | -15,730 | |
| Dir | 588.2K | $17.38M | - | |
| Other | 69.8K | $2.06M | -20,822 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 20, 2025 | Slingsby Brian Taylor48 | Director, 10% Owner | Sell | 1,000,000 | $43.35 | $43,350,000.00 | -11.2% | -33.3% | - | |
| Nov 13, 2025 | Karydas Daphne | Director | Sale+OE | 15,000 | $45.99 | $689,797.08 | -75.4% | -32.8% | - | |
| Nov 13, 2025 | Gold Alexander M61 | Director | Sale+OE | 34,675 | $45.45 | $1,576,094.67 | -83.3% | -32.8% | - | |
| Nov 11, 2025 | Congleton Jon47 | Chief Executive Officer | Sell | 200,000 | $45.44 | $9,088,498.87 | -4.3% | -32.6% | - | |
| Nov 11, 2025 | Levy Adam Scott | CFO And Secretary | Sale+OE | 119,524 | $44.88 | $5,363,715.88 | -12.1% | -32.6% | - | |
| Oct 15, 2025 | Rodman David Malcom58 | Chief Medical Officer | Sell | 10,369 | $43.01 | $445,982.10 | -12.7% | -24.0% | - | |
| Oct 13, 2025 | Levy Adam Scott | CFO And Secretary | Sell | 10,758 | $42.01 | $451,983.56 | -4.3% | -23.4% | - | |
| Oct 13, 2025 | Congleton Jon47 | Chief Executive Officer | Sell | 15,100 | $42.67 | $644,326.87 | -0.9% | -23.4% | - | |
| Sep 15, 2025 | Rodman David Malcom58 | Chief Medical Officer | Sell | 11,367 | $36.00 | $409,265.98 | -6.4% | -0.5% | - | |
| Sep 4, 2025 | Ra Capital Management, L.P.52 | Director | Buy | 1,176,470 | $25.50 | $29,999,985.00 | +27.5% | +18.4% | - |